This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falk, R.
Right arrow Articles by Polacheck, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falk, R.
Right arrow Articles by Polacheck, I.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2003, p. 911, Vol. 41, No. 2
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.2.911.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Multidrug-Resistant Trichosporon asahii Isolates Are Susceptible to Voriconazole


arrow
LETTER
 
We recently described the recovery of six clinical isolates of Trichosporon asahii from nongranulocytopenic patients that exhibited reduced susceptibilities to amphotericin B, flucytosine, ketoconazole, itraconazole, and fluconazole (7). In a recent paper Paphitou et al. reported (6) that the new investigational triazoles including voriconazole were highly potent against 24 isolates of Trichosporon asahii (MIC and minimal fungicidal concentration [MFC] of 0.25 and 0.5 mg/liter, respectively), confirming the prior observation that voriconazole has a lower MIC for T. asahii than do other azoles (4).

Recently, the NCCLS has recommended testing yeasts for susceptibility to new triazoles including voriconazole (M27-A2) (5), and a commercial Etest kit for voriconazole has become available. Consequently, we performed susceptibility testing for our T. asahii multidrug-resistant isolates against voriconazole (7). The results (Table 1) strongly indicate that these six isolates, which exhibit reduced susceptibilities to fluconazole, are highly susceptible to voriconazole. The MICs and MFCs of voriconazole for these isolates are close (0.125 to 0.25 and 0.25 to 1.0 mg/liter, respectively), suggesting fungicidal activity of voriconazole.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Susceptibilities of T. asahii isolates to fluconazole and voriconazole

Voriconazole is an expanded-spectrum synthetic triazole derivative of fluconazole. It inhibits the enzyme lanosterol 14-{alpha}-demethylase of Candida albicans and Aspergillus fumigatus with potencies 1.6 and 160 times greater, respectively, than those of fluconazole (3). Its potent fungicidal activity is likely due to the high affinity of voriconazole for fungal 14-{alpha}-demethylase, a concept supported by ultrastructural and biochemical analysis (1). However, unlike fluconazole, voriconazole also inhibits 24-methylene dihydrolanosterol demethylation of certain yeasts and filamentous fungi (3). These two reasons may explain why voriconazole may be effective in the treatment of mycoses like trichosporonosis that do not respond to other azoles. According to a new study, voriconazole is "superior" to amphotericin B for treating life-threatening invasive aspergillosis (2) and was recently approved in some European countries for the treatment of invasive aspergillosis.

In our previous paper (7) we emphasized the importance of the patient's basic immune status in determining the outcome of T. asahii infection. We concluded that in vitro resistance to antifungal drugs might not be critical in immunocompetent patients. However, immunocompromised patients may be dependent on fungicidal drug activity, so that infection with multidrug-resistant T. asahii isolates may be fatal in this population. Our new data with the low MICs and MFCs of voriconazole that confirm other in vitro studies suggest that voriconazole may offer a clinical solution in trichosporonosis when other antifungal drugs fail.


arrow
REFERENCES
 
    1
  1. Ghannoum, M. A., and D. M. Kuhn. 2002. Voriconazole—better chances for patients with invasive mycoses. Eur. J. Med. Res. 7:242-256.[Medline]
    2. 2
  2. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.[Abstract/Free Full Text]
    3. 3
  3. Masia Canuto, M., and F. Gutierrez Rodero. 2002. Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis. 2:550-563.[CrossRef][Medline]
    4. 4
  4. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, Jr., and M. G. Rinaldi. 1998. In vitro activity of voriconazole against selected fungi. Med. Mycol. 36:239-242.[CrossRef][Medline]
    5. 5
  5. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard, 2nd ed. M27-A2, vol. 22. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    6. 6
  6. Paphitou, N. I., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2002. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. 46:1144-1146.[Abstract/Free Full Text]
    7. 7
  7. Wolf, D. G., R. Falk, M. Hacham, B. Theelen, T. Boekhout, G. Scorzetti, M. Shapiro, C. Block, I. F. Salkin, and I. Polacheck. 2001. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J. Clin. Microbiol. 39:4420-4425.[Abstract/Free Full Text]
Rama Falk
Dana G. Wolf
Mervyn Shapiro
Itzhack Polacheck*
Department of Clinical Microbiology and Infectious Diseases
The Hebrew University-Hadassah Medical Center
P.O. Box 12000
Jerusalem 91120, Israel

* Phone: 972-2-677-6592, Fax: 972-2-641-9545, E-mail: Itzhack.Polacheck{at}huji.ac.il

Journal of Clinical Microbiology, February 2003, p. 911, Vol. 41, No. 2
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.2.911.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Serena, C., Gilgado, F., Marine, M., Pastor, F. J., Guarro, J. (2006). Efficacy of voriconazole in a Guinea pig model of invasive trichosporonosis.. Antimicrob. Agents Chemother. 50: 2240-2243 [Abstract] [Full Text]  
  • Rodriguez-Tudela, J. L., Diaz-Guerra, T. M., Mellado, E., Cano, V., Tapia, C., Perkins, A., Gomez-Lopez, A., Rodero, L., Cuenca-Estrella, M. (2005). Susceptibility Patterns and Molecular Identification of Trichosporon Species. Antimicrob. Agents Chemother. 49: 4026-4034 [Abstract] [Full Text]  
  • Girmenia, C., Pagano, L., Martino, B., D'Antonio, D., Fanci, R., Specchia, G., Melillo, L., Buelli, M., Pizzarelli, G., Venditti, M., Martino, P., the GIMEMA Infection Program, (2005). Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature. J. Clin. Microbiol. 43: 1818-1828 [Abstract] [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falk, R.
Right arrow Articles by Polacheck, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falk, R.
Right arrow Articles by Polacheck, I.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»